Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.

被引：3
|
作者：
Lau, Sally C. M.
Perdrizet, Kirstin
Mata, Danilo Giffoni de Mello Morais
Fung, Andrea S.
Liu, Geoffrey
Bradbury, Penelope Ann
Shepherd, Frances A.
Sacher, Adrian G.
Sheffield, Brandon
Hwang, David
Tsao, Ming Sound
Cheng, Susanna Y.
Cheema, Parneet
Leighl, Natasha B.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Canc Ctr Southeastern Ontario, Kingston, ON, Canada
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[7] William Osler Hlth Ctr, Brampton, ON, Canada
[8] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada
[9] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[10] Univ Toronto, William Osler Hlth Syst, Toronto, ON, Canada
[11] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21123
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation
    Basse, Clemence
    Blancard, Lucie Regaldo-Saint
    BULLETIN DU CANCER, 2023, 110 (09)
  • [2] Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
    Leighl, N.
    Cho, B. C.
    Hiret, S.
    Han, J. -Y.
    Lee, K. H.
    Perez, C. Llacer
    Krebs, M. G.
    De Braud, F.
    Haura, E.
    Sanborn, R. E.
    Yang, J. C. -H.
    Shu, C. A.
    Goto, K.
    Nishio, M.
    Zhao, J.
    Wang, Z.
    Tomasini, P.
    Felip, E.
    Goldman, J. W.
    Ou, S. -H. I.
    Boyer, M.
    Gao, G.
    Qu, S.
    Curtin, J. C.
    Lyu, X.
    Roshak, A.
    Schnepp, R. W.
    Kim, P.
    Mertz, J.
    Thayu, M.
    Shreeve, S. M.
    Knoblauch, R. E.
    Spira, A. I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S93 - S94
  • [3] Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
    Tanaka, Hisashi
    Taima, Kageaki
    Makiguchi, Tomonori
    Nakagawa, Junichi
    Niioka, Takenori
    Tasaka, Sadatomo
    CANCER COMMUNICATIONS, 2021, 41 (01) : 83 - 87
  • [4] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Ahn, M-J.
    Sakai, H.
    Morise, M.
    Kato, T.
    Chen, Y-M.
    Han, J-Y.
    Yang, J-J.
    Zhao, J.
    Huang, J.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Le, X.
    Paik, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S41 - S42
  • [5] Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report
    Jiao, Yang
    Fang, Chen
    Yang, Yuchen
    Shao, Lin
    Huang, Yi
    Sun, Qinying
    Dong, Yuchao
    ONCOTARGETS AND THERAPY, 2021, 14 : 2417 - 2421
  • [6] Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutation
    Smith, Miles
    Carter, Mat
    Woodhouse, Laura
    Adderley, Helen
    Morrissey, George
    Brown, Kate
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin R.
    LUNG CANCER, 2024, 190
  • [7] Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
    Heist, Rebecca S.
    Sequist, Lecia V.
    Borger, Darrell
    Gainor, Justin F.
    Arellano, Ronald S.
    Le, Long P.
    Dias-Santagata, Dora
    Clark, Jeffrey W.
    Engelman, Jeffrey A.
    Shaw, Alice T.
    Lafrate, A. John
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) : 1242 - 1245
  • [8] Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Le, X.
    Cho, B. C.
    Han, J-Y.
    Morise, M.
    Chen, Y-M.
    Kang, J-H.
    Kato, T.
    Takeoka, H.
    Chikamori, K.
    Sakai, H.
    Park, K.
    Wu, Y-L.
    Schumacher, K.
    Bruns, R.
    Straub, J.
    Paik, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1390 - S1391
  • [9] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.
    Kato, Terufumi
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Sakai, Hiroshi
    Morise, Masahiro
    Chen, Yuh-Min
    Han, Ji-Youn
    Yang, Jin-Ji
    Zhao, Jun
    Huang, Jason
    Berghoff, Karin
    Bruns, Rolf
    Vioix, Helene
    Otto, Gordon
    Le, Xiuning
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
    Smit, E. F.
    Garassino, M. C.
    Felip, E.
    Sakai, H.
    Le, X.
    Veillon, R.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Thomas, M.
    Viteri Ramirez, S.
    Berghoff, K.
    Bruns, R.
    Otto, G. P.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1002 - S1003
12345